nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—HTR2C—obesity	0.149	1	CbGaD
Sorafenib—CYP2B6—Benzphetamine—obesity	0.0328	0.0823	CbGbCtD
Sorafenib—CYP2B6—Bupropion—obesity	0.0279	0.07	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Cimetidine—obesity	0.0215	0.054	CbGbCtD
Sorafenib—CYP3A7—Cimetidine—obesity	0.0215	0.054	CbGbCtD
Sorafenib—CYP2C8—Bupropion—obesity	0.0211	0.053	CbGbCtD
Sorafenib—CYP1A2—Phentermine—obesity	0.0192	0.0483	CbGbCtD
Sorafenib—CYP1A2—Phenylpropanolamine—obesity	0.0183	0.046	CbGbCtD
Sorafenib—CYP2C9—Phentermine—obesity	0.0173	0.0435	CbGbCtD
Sorafenib—CYP1A2—Bupropion—obesity	0.0163	0.041	CbGbCtD
Sorafenib—CYP3A5—Cimetidine—obesity	0.0161	0.0405	CbGbCtD
Sorafenib—CYP2D6—Phentermine—obesity	0.0158	0.0398	CbGbCtD
Sorafenib—CYP2C8—Cimetidine—obesity	0.0155	0.0389	CbGbCtD
Sorafenib—CYP2C9—Bupropion—obesity	0.0147	0.037	CbGbCtD
Sorafenib—CYP2D6—Bupropion—obesity	0.0135	0.0338	CbGbCtD
Sorafenib—CYP3A4—Sibutramine—obesity	0.0133	0.0334	CbGbCtD
Sorafenib—CYP2C19—Cimetidine—obesity	0.013	0.0326	CbGbCtD
Sorafenib—CYP2D6—Methamphetamine—obesity	0.0127	0.0318	CbGbCtD
Sorafenib—CYP1A2—Cimetidine—obesity	0.012	0.0301	CbGbCtD
Sorafenib—CYP2C9—Cimetidine—obesity	0.0108	0.0271	CbGbCtD
Sorafenib—ABCB1—Cimetidine—obesity	0.0105	0.0263	CbGbCtD
Sorafenib—CYP3A4—Benzphetamine—obesity	0.0101	0.0253	CbGbCtD
Sorafenib—CYP2D6—Cimetidine—obesity	0.00988	0.0248	CbGbCtD
Sorafenib—CYP3A4—Bupropion—obesity	0.00856	0.0215	CbGbCtD
Sorafenib—CYP2C19—Topiramate—obesity	0.00851	0.0214	CbGbCtD
Sorafenib—CYP3A4—Orlistat—obesity	0.00698	0.0175	CbGbCtD
Sorafenib—CYP3A4—Cimetidine—obesity	0.00628	0.0158	CbGbCtD
Sorafenib—CYP3A4—Topiramate—obesity	0.00411	0.0103	CbGbCtD
Sorafenib—MAP2K5—hindbrain—obesity	0.000769	0.00696	CbGeAlD
Sorafenib—MAPK11—adipose tissue—obesity	0.000751	0.00679	CbGeAlD
Sorafenib—CDK7—adipose tissue—obesity	0.000739	0.00668	CbGeAlD
Sorafenib—TAOK2—pituitary gland—obesity	0.000736	0.00666	CbGeAlD
Sorafenib—TAOK2—adipose tissue—obesity	0.000733	0.00663	CbGeAlD
Sorafenib—TIE1—adrenal cortex—obesity	0.000726	0.00657	CbGeAlD
Sorafenib—ZAK—cardiovascular system—obesity	0.000724	0.00655	CbGeAlD
Sorafenib—FLT4—respiratory system—obesity	0.000715	0.00646	CbGeAlD
Sorafenib—HIPK3—cardiovascular system—obesity	0.000709	0.00641	CbGeAlD
Sorafenib—MKNK2—islet of Langerhans—obesity	0.000685	0.0062	CbGeAlD
Sorafenib—KIT—hindbrain—obesity	0.000682	0.00617	CbGeAlD
Sorafenib—MAPK11—adrenal gland—obesity	0.000674	0.00609	CbGeAlD
Sorafenib—KIT—gall bladder—obesity	0.000672	0.00608	CbGeAlD
Sorafenib—EPHX2—adrenal cortex—obesity	0.000665	0.00602	CbGeAlD
Sorafenib—HIPK4—endocrine gland—obesity	0.000663	0.006	CbGeAlD
Sorafenib—CDK7—adrenal gland—obesity	0.000663	0.006	CbGeAlD
Sorafenib—TIE1—cardiovascular system—obesity	0.000662	0.00599	CbGeAlD
Sorafenib—TAOK2—adrenal gland—obesity	0.000658	0.00595	CbGeAlD
Sorafenib—PDGFRB—gall bladder—obesity	0.000657	0.00594	CbGeAlD
Sorafenib—AURKC—adrenal gland—obesity	0.000652	0.0059	CbGeAlD
Sorafenib—MKNK2—respiratory system—obesity	0.000647	0.00585	CbGeAlD
Sorafenib—ZAK—adipose tissue—obesity	0.000639	0.00578	CbGeAlD
Sorafenib—HIPK3—pituitary gland—obesity	0.000627	0.00568	CbGeAlD
Sorafenib—HIPK3—adipose tissue—obesity	0.000625	0.00565	CbGeAlD
Sorafenib—RALBP1—islet of Langerhans—obesity	0.000619	0.0056	CbGeAlD
Sorafenib—FLT3—cardiovascular system—obesity	0.000603	0.00545	CbGeAlD
Sorafenib—ZAK—digestive system—obesity	0.000601	0.00544	CbGeAlD
Sorafenib—FLT4—adrenal cortex—obesity	0.0006	0.00543	CbGeAlD
Sorafenib—FLT1—islet of Langerhans—obesity	0.000588	0.00532	CbGeAlD
Sorafenib—HIPK3—digestive system—obesity	0.000588	0.00532	CbGeAlD
Sorafenib—RAF1—islet of Langerhans—obesity	0.000585	0.00529	CbGeAlD
Sorafenib—RALBP1—respiratory system—obesity	0.000584	0.00528	CbGeAlD
Sorafenib—TIE1—adipose tissue—obesity	0.000584	0.00528	CbGeAlD
Sorafenib—EPHB6—islet of Langerhans—obesity	0.000582	0.00526	CbGeAlD
Sorafenib—CDK7—endocrine gland—obesity	0.000575	0.0052	CbGeAlD
Sorafenib—ZAK—adrenal gland—obesity	0.000573	0.00518	CbGeAlD
Sorafenib—AURKC—endocrine gland—obesity	0.000566	0.00512	CbGeAlD
Sorafenib—BRAF—pituitary gland—obesity	0.000562	0.00509	CbGeAlD
Sorafenib—HIPK3—adrenal gland—obesity	0.000561	0.00507	CbGeAlD
Sorafenib—MAP3K7—adrenal cortex—obesity	0.00056	0.00507	CbGeAlD
Sorafenib—BRAF—adipose tissue—obesity	0.00056	0.00507	CbGeAlD
Sorafenib—FLT1—respiratory system—obesity	0.000556	0.00503	CbGeAlD
Sorafenib—RAF1—respiratory system—obesity	0.000552	0.005	CbGeAlD
Sorafenib—FLT4—cardiovascular system—obesity	0.000547	0.00495	CbGeAlD
Sorafenib—MKNK2—adrenal cortex—obesity	0.000543	0.00491	CbGeAlD
Sorafenib—EPHX2—pituitary gland—obesity	0.000537	0.00486	CbGeAlD
Sorafenib—MKNK1—adrenal cortex—obesity	0.000536	0.00485	CbGeAlD
Sorafenib—EPHX2—adipose tissue—obesity	0.000535	0.00484	CbGeAlD
Sorafenib—STK10—respiratory system—obesity	0.000526	0.00476	CbGeAlD
Sorafenib—EPHA6—endocrine gland—obesity	0.000524	0.00474	CbGeAlD
Sorafenib—TIE1—adrenal gland—obesity	0.000524	0.00474	CbGeAlD
Sorafenib—PDGFRA—respiratory system—obesity	0.000521	0.00471	CbGeAlD
Sorafenib—CDK7—liver—obesity	0.000518	0.00469	CbGeAlD
Sorafenib—TAOK2—liver—obesity	0.000514	0.00465	CbGeAlD
Sorafenib—BRAF—adrenal gland—obesity	0.000502	0.00454	CbGeAlD
Sorafenib—ZAK—endocrine gland—obesity	0.000497	0.00449	CbGeAlD
Sorafenib—MKNK2—cardiovascular system—obesity	0.000495	0.00448	CbGeAlD
Sorafenib—RALBP1—adrenal cortex—obesity	0.00049	0.00443	CbGeAlD
Sorafenib—MKNK1—cardiovascular system—obesity	0.000489	0.00443	CbGeAlD
Sorafenib—HIPK3—endocrine gland—obesity	0.000486	0.0044	CbGeAlD
Sorafenib—FLT4—adipose tissue—obesity	0.000483	0.00437	CbGeAlD
Sorafenib—EPHX2—adrenal gland—obesity	0.00048	0.00434	CbGeAlD
Sorafenib—FGFR1—pituitary gland—obesity	0.000478	0.00432	CbGeAlD
Sorafenib—FLT3—adrenal gland—obesity	0.000477	0.00431	CbGeAlD
Sorafenib—FGFR1—adipose tissue—obesity	0.000476	0.00431	CbGeAlD
Sorafenib—KDR—respiratory system—obesity	0.00047	0.00425	CbGeAlD
Sorafenib—FLT1—adrenal cortex—obesity	0.000466	0.00422	CbGeAlD
Sorafenib—RAF1—adrenal cortex—obesity	0.000464	0.00419	CbGeAlD
Sorafenib—UGT1A9—digestive system—obesity	0.000461	0.00417	CbGeAlD
Sorafenib—CSF1R—respiratory system—obesity	0.000458	0.00415	CbGeAlD
Sorafenib—MAP3K7—pituitary gland—obesity	0.000453	0.00409	CbGeAlD
Sorafenib—MAP3K7—adipose tissue—obesity	0.000451	0.00408	CbGeAlD
Sorafenib—ZAK—liver—obesity	0.000448	0.00405	CbGeAlD
Sorafenib—RALBP1—cardiovascular system—obesity	0.000447	0.00405	CbGeAlD
Sorafenib—MKNK2—pituitary gland—obesity	0.000439	0.00397	CbGeAlD
Sorafenib—HIPK3—liver—obesity	0.000438	0.00396	CbGeAlD
Sorafenib—MKNK2—adipose tissue—obesity	0.000437	0.00395	CbGeAlD
Sorafenib—MKNK1—pituitary gland—obesity	0.000433	0.00392	CbGeAlD
Sorafenib—FLT4—adrenal gland—obesity	0.000433	0.00392	CbGeAlD
Sorafenib—MKNK1—adipose tissue—obesity	0.000431	0.0039	CbGeAlD
Sorafenib—PDGFRB—islet of Langerhans—obesity	0.000431	0.00389	CbGeAlD
Sorafenib—RET—pituitary gland—obesity	0.000428	0.00387	CbGeAlD
Sorafenib—FGFR1—adrenal gland—obesity	0.000427	0.00386	CbGeAlD
Sorafenib—FLT1—cardiovascular system—obesity	0.000426	0.00385	CbGeAlD
Sorafenib—RAF1—cardiovascular system—obesity	0.000423	0.00383	CbGeAlD
Sorafenib—KIT—respiratory system—obesity	0.000416	0.00377	CbGeAlD
Sorafenib—FLT3—endocrine gland—obesity	0.000413	0.00374	CbGeAlD
Sorafenib—MKNK2—digestive system—obesity	0.000411	0.00372	CbGeAlD
Sorafenib—TIE1—liver—obesity	0.00041	0.00371	CbGeAlD
Sorafenib—PDGFRB—respiratory system—obesity	0.000407	0.00368	CbGeAlD
Sorafenib—MKNK1—digestive system—obesity	0.000406	0.00367	CbGeAlD
Sorafenib—MAP3K7—adrenal gland—obesity	0.000404	0.00366	CbGeAlD
Sorafenib—STK10—cardiovascular system—obesity	0.000403	0.00364	CbGeAlD
Sorafenib—RET—digestive system—obesity	0.000401	0.00363	CbGeAlD
Sorafenib—PDGFRA—cardiovascular system—obesity	0.000399	0.00361	CbGeAlD
Sorafenib—RALBP1—pituitary gland—obesity	0.000396	0.00358	CbGeAlD
Sorafenib—RALBP1—adipose tissue—obesity	0.000395	0.00357	CbGeAlD
Sorafenib—KDR—adrenal cortex—obesity	0.000394	0.00357	CbGeAlD
Sorafenib—MAP2K5—adrenal cortex—obesity	0.000394	0.00357	CbGeAlD
Sorafenib—BRAF—liver—obesity	0.000393	0.00355	CbGeAlD
Sorafenib—MKNK2—adrenal gland—obesity	0.000392	0.00354	CbGeAlD
Sorafenib—MKNK1—adrenal gland—obesity	0.000387	0.0035	CbGeAlD
Sorafenib—CSF1R—adrenal cortex—obesity	0.000385	0.00348	CbGeAlD
Sorafenib—RET—adrenal gland—obesity	0.000382	0.00346	CbGeAlD
Sorafenib—UGT1A9—endocrine gland—obesity	0.000381	0.00344	CbGeAlD
Sorafenib—FLT1—pituitary gland—obesity	0.000377	0.00341	CbGeAlD
Sorafenib—FLT4—endocrine gland—obesity	0.000375	0.0034	CbGeAlD
Sorafenib—EPHX2—liver—obesity	0.000375	0.0034	CbGeAlD
Sorafenib—FLT1—adipose tissue—obesity	0.000375	0.00339	CbGeAlD
Sorafenib—RAF1—pituitary gland—obesity	0.000375	0.00339	CbGeAlD
Sorafenib—RAF1—adipose tissue—obesity	0.000373	0.00337	CbGeAlD
Sorafenib—FLT3—liver—obesity	0.000373	0.00337	CbGeAlD
Sorafenib—EPHB6—pituitary gland—obesity	0.000372	0.00337	CbGeAlD
Sorafenib—RALBP1—digestive system—obesity	0.000371	0.00336	CbGeAlD
Sorafenib—EPHB6—adipose tissue—obesity	0.000371	0.00336	CbGeAlD
Sorafenib—KDR—cardiovascular system—obesity	0.00036	0.00325	CbGeAlD
Sorafenib—MAP2K5—cardiovascular system—obesity	0.00036	0.00325	CbGeAlD
Sorafenib—STK10—adipose tissue—obesity	0.000355	0.00321	CbGeAlD
Sorafenib—RALBP1—adrenal gland—obesity	0.000354	0.0032	CbGeAlD
Sorafenib—FLT1—digestive system—obesity	0.000353	0.0032	CbGeAlD
Sorafenib—PDGFRA—adipose tissue—obesity	0.000352	0.00318	CbGeAlD
Sorafenib—RAF1—digestive system—obesity	0.000351	0.00318	CbGeAlD
Sorafenib—CSF1R—cardiovascular system—obesity	0.000351	0.00318	CbGeAlD
Sorafenib—UGT1A9—liver—obesity	0.000343	0.00311	CbGeAlD
Sorafenib—PDGFRB—adrenal cortex—obesity	0.000341	0.00309	CbGeAlD
Sorafenib—MKNK2—endocrine gland—obesity	0.00034	0.00307	CbGeAlD
Sorafenib—FLT4—liver—obesity	0.000338	0.00306	CbGeAlD
Sorafenib—FLT1—adrenal gland—obesity	0.000337	0.00305	CbGeAlD
Sorafenib—MKNK1—endocrine gland—obesity	0.000336	0.00304	CbGeAlD
Sorafenib—RAF1—adrenal gland—obesity	0.000335	0.00303	CbGeAlD
Sorafenib—STK10—digestive system—obesity	0.000334	0.00302	CbGeAlD
Sorafenib—FGFR1—liver—obesity	0.000334	0.00302	CbGeAlD
Sorafenib—EPHB6—adrenal gland—obesity	0.000333	0.00301	CbGeAlD
Sorafenib—RET—endocrine gland—obesity	0.000331	0.003	CbGeAlD
Sorafenib—PDGFRA—digestive system—obesity	0.000331	0.00299	CbGeAlD
Sorafenib—KIT—cardiovascular system—obesity	0.000319	0.00288	CbGeAlD
Sorafenib—STK10—adrenal gland—obesity	0.000319	0.00288	CbGeAlD
Sorafenib—MAP2K5—pituitary gland—obesity	0.000319	0.00288	CbGeAlD
Sorafenib—KDR—pituitary gland—obesity	0.000319	0.00288	CbGeAlD
Sorafenib—KDR—adipose tissue—obesity	0.000317	0.00287	CbGeAlD
Sorafenib—MAP2K5—adipose tissue—obesity	0.000317	0.00287	CbGeAlD
Sorafenib—CYP3A7—endocrine gland—obesity	0.000317	0.00286	CbGeAlD
Sorafenib—MAP3K7—liver—obesity	0.000316	0.00286	CbGeAlD
Sorafenib—UGT1A1—digestive system—obesity	0.000316	0.00286	CbGeAlD
Sorafenib—PDGFRA—adrenal gland—obesity	0.000315	0.00285	CbGeAlD
Sorafenib—PDGFRB—cardiovascular system—obesity	0.000311	0.00282	CbGeAlD
Sorafenib—CSF1R—pituitary gland—obesity	0.000311	0.00281	CbGeAlD
Sorafenib—CSF1R—adipose tissue—obesity	0.00031	0.0028	CbGeAlD
Sorafenib—RALBP1—endocrine gland—obesity	0.000307	0.00278	CbGeAlD
Sorafenib—MKNK2—liver—obesity	0.000306	0.00277	CbGeAlD
Sorafenib—MKNK1—liver—obesity	0.000303	0.00274	CbGeAlD
Sorafenib—KDR—digestive system—obesity	0.000299	0.0027	CbGeAlD
Sorafenib—FLT1—endocrine gland—obesity	0.000292	0.00264	CbGeAlD
Sorafenib—CSF1R—digestive system—obesity	0.000291	0.00264	CbGeAlD
Sorafenib—RAF1—endocrine gland—obesity	0.00029	0.00263	CbGeAlD
Sorafenib—CYP3A7—liver—obesity	0.000285	0.00258	CbGeAlD
Sorafenib—KDR—adrenal gland—obesity	0.000285	0.00257	CbGeAlD
Sorafenib—MAP2K5—adrenal gland—obesity	0.000285	0.00257	CbGeAlD
Sorafenib—KIT—pituitary gland—obesity	0.000282	0.00255	CbGeAlD
Sorafenib—KIT—adipose tissue—obesity	0.000281	0.00254	CbGeAlD
Sorafenib—CSF1R—adrenal gland—obesity	0.000278	0.00251	CbGeAlD
Sorafenib—RALBP1—liver—obesity	0.000277	0.0025	CbGeAlD
Sorafenib—STK10—endocrine gland—obesity	0.000276	0.0025	CbGeAlD
Sorafenib—PDGFRB—pituitary gland—obesity	0.000276	0.00249	CbGeAlD
Sorafenib—PDGFRB—adipose tissue—obesity	0.000275	0.00248	CbGeAlD
Sorafenib—PDGFRA—endocrine gland—obesity	0.000274	0.00247	CbGeAlD
Sorafenib—HTR2B—adrenal cortex—obesity	0.00027	0.00244	CbGeAlD
Sorafenib—KIT—digestive system—obesity	0.000265	0.00239	CbGeAlD
Sorafenib—FLT1—liver—obesity	0.000263	0.00238	CbGeAlD
Sorafenib—RAF1—liver—obesity	0.000262	0.00237	CbGeAlD
Sorafenib—UGT1A1—endocrine gland—obesity	0.000261	0.00236	CbGeAlD
Sorafenib—PDGFRB—digestive system—obesity	0.000258	0.00234	CbGeAlD
Sorafenib—CYP2D6—hindbrain—obesity	0.000256	0.00232	CbGeAlD
Sorafenib—KIT—adrenal gland—obesity	0.000252	0.00228	CbGeAlD
Sorafenib—STK10—liver—obesity	0.000249	0.00225	CbGeAlD
Sorafenib—KDR—endocrine gland—obesity	0.000247	0.00223	CbGeAlD
Sorafenib—MAP2K5—endocrine gland—obesity	0.000247	0.00223	CbGeAlD
Sorafenib—PDGFRA—liver—obesity	0.000247	0.00223	CbGeAlD
Sorafenib—HTR2B—cardiovascular system—obesity	0.000247	0.00223	CbGeAlD
Sorafenib—PDGFRB—adrenal gland—obesity	0.000246	0.00223	CbGeAlD
Sorafenib—Hypersensitivity—Cimetidine—obesity	0.000246	0.00159	CcSEcCtD
Sorafenib—Pneumonia—Bupropion—obesity	0.000245	0.00159	CcSEcCtD
Sorafenib—Infestation NOS—Bupropion—obesity	0.000244	0.00158	CcSEcCtD
Sorafenib—Infestation—Bupropion—obesity	0.000244	0.00158	CcSEcCtD
Sorafenib—CYP3A7-CYP3A51P—liver—obesity	0.000243	0.0022	CbGeAlD
Sorafenib—Stevens-Johnson syndrome—Bupropion—obesity	0.000241	0.00156	CcSEcCtD
Sorafenib—CSF1R—endocrine gland—obesity	0.000241	0.00218	CbGeAlD
Sorafenib—Acute coronary syndrome—Bupropion—obesity	0.00024	0.00155	CcSEcCtD
Sorafenib—Diarrhoea—Diethylpropion—obesity	0.00024	0.00155	CcSEcCtD
Sorafenib—Nausea—Phentermine—obesity	0.000239	0.00155	CcSEcCtD
Sorafenib—Asthenia—Cimetidine—obesity	0.000239	0.00155	CcSEcCtD
Sorafenib—Myocardial infarction—Bupropion—obesity	0.000239	0.00154	CcSEcCtD
Sorafenib—Neuropathy peripheral—Bupropion—obesity	0.000239	0.00154	CcSEcCtD
Sorafenib—Jaundice—Bupropion—obesity	0.000237	0.00154	CcSEcCtD
Sorafenib—Stomatitis—Bupropion—obesity	0.000237	0.00154	CcSEcCtD
Sorafenib—UGT1A1—liver—obesity	0.000235	0.00213	CbGeAlD
Sorafenib—Immune system disorder—Orlistat—obesity	0.000234	0.00151	CcSEcCtD
Sorafenib—Tinnitus—Sibutramine—obesity	0.000234	0.00151	CcSEcCtD
Sorafenib—Mediastinal disorder—Orlistat—obesity	0.000234	0.00151	CcSEcCtD
Sorafenib—Dizziness—Diethylpropion—obesity	0.000232	0.0015	CcSEcCtD
Sorafenib—Epistaxis—Bupropion—obesity	0.00023	0.00149	CcSEcCtD
Sorafenib—Alopecia—Orlistat—obesity	0.000229	0.00148	CcSEcCtD
Sorafenib—Diarrhoea—Cimetidine—obesity	0.000228	0.00148	CcSEcCtD
Sorafenib—Angiopathy—Sibutramine—obesity	0.000228	0.00147	CcSEcCtD
Sorafenib—Mental disorder—Orlistat—obesity	0.000227	0.00147	CcSEcCtD
Sorafenib—Immune system disorder—Sibutramine—obesity	0.000227	0.00147	CcSEcCtD
Sorafenib—Malnutrition—Orlistat—obesity	0.000226	0.00146	CcSEcCtD
Sorafenib—CYP3A5—islet of Langerhans—obesity	0.000225	0.00203	CbGeAlD
Sorafenib—Eczema—Topiramate—obesity	0.000224	0.00145	CcSEcCtD
Sorafenib—Hepatic failure—Topiramate—obesity	0.000224	0.00145	CcSEcCtD
Sorafenib—Arrhythmia—Sibutramine—obesity	0.000224	0.00145	CcSEcCtD
Sorafenib—Vomiting—Diethylpropion—obesity	0.000223	0.00144	CcSEcCtD
Sorafenib—KDR—liver—obesity	0.000222	0.00201	CbGeAlD
Sorafenib—MAP2K5—liver—obesity	0.000222	0.00201	CbGeAlD
Sorafenib—Alopecia—Sibutramine—obesity	0.000222	0.00143	CcSEcCtD
Sorafenib—Rash—Diethylpropion—obesity	0.000221	0.00143	CcSEcCtD
Sorafenib—Dysgeusia—Orlistat—obesity	0.000221	0.00143	CcSEcCtD
Sorafenib—Dermatitis—Diethylpropion—obesity	0.000221	0.00143	CcSEcCtD
Sorafenib—Dizziness—Cimetidine—obesity	0.000221	0.00143	CcSEcCtD
Sorafenib—CYP1A2—respiratory system—obesity	0.00022	0.00199	CbGeAlD
Sorafenib—Haemoglobin—Bupropion—obesity	0.00022	0.00142	CcSEcCtD
Sorafenib—Headache—Diethylpropion—obesity	0.00022	0.00142	CcSEcCtD
Sorafenib—KIT—endocrine gland—obesity	0.000219	0.00198	CbGeAlD
Sorafenib—Haemorrhage—Bupropion—obesity	0.000219	0.00141	CcSEcCtD
Sorafenib—ABCC4—adipose tissue—obesity	0.000219	0.00198	CbGeAlD
Sorafenib—Malnutrition—Sibutramine—obesity	0.000218	0.00141	CcSEcCtD
Sorafenib—HTR2B—adipose tissue—obesity	0.000217	0.00197	CbGeAlD
Sorafenib—CSF1R—liver—obesity	0.000217	0.00196	CbGeAlD
Sorafenib—Muscle spasms—Orlistat—obesity	0.000217	0.0014	CcSEcCtD
Sorafenib—Urinary tract disorder—Bupropion—obesity	0.000216	0.0014	CcSEcCtD
Sorafenib—Connective tissue disorder—Bupropion—obesity	0.000215	0.00139	CcSEcCtD
Sorafenib—Urethral disorder—Bupropion—obesity	0.000214	0.00139	CcSEcCtD
Sorafenib—Dysgeusia—Sibutramine—obesity	0.000214	0.00138	CcSEcCtD
Sorafenib—PDGFRB—endocrine gland—obesity	0.000214	0.00193	CbGeAlD
Sorafenib—CYP3A5—respiratory system—obesity	0.000212	0.00192	CbGeAlD
Sorafenib—Vomiting—Cimetidine—obesity	0.000212	0.00137	CcSEcCtD
Sorafenib—CYP2B6—respiratory system—obesity	0.000211	0.00191	CbGeAlD
Sorafenib—Rash—Cimetidine—obesity	0.00021	0.00136	CcSEcCtD
Sorafenib—Dermatitis—Cimetidine—obesity	0.00021	0.00136	CcSEcCtD
Sorafenib—Muscle spasms—Sibutramine—obesity	0.00021	0.00136	CcSEcCtD
Sorafenib—Headache—Cimetidine—obesity	0.000209	0.00135	CcSEcCtD
Sorafenib—Nausea—Diethylpropion—obesity	0.000208	0.00135	CcSEcCtD
Sorafenib—Erythema multiforme—Bupropion—obesity	0.000207	0.00134	CcSEcCtD
Sorafenib—Angioedema—Orlistat—obesity	0.000206	0.00133	CcSEcCtD
Sorafenib—ABCC4—digestive system—obesity	0.000206	0.00186	CbGeAlD
Sorafenib—HTR2B—digestive system—obesity	0.000205	0.00185	CbGeAlD
Sorafenib—Tinnitus—Bupropion—obesity	0.000204	0.00132	CcSEcCtD
Sorafenib—Flushing—Bupropion—obesity	0.000203	0.00131	CcSEcCtD
Sorafenib—Cardiac disorder—Bupropion—obesity	0.000203	0.00131	CcSEcCtD
Sorafenib—Hyponatraemia—Topiramate—obesity	0.000202	0.00131	CcSEcCtD
Sorafenib—Anaemia—Sibutramine—obesity	0.000202	0.00131	CcSEcCtD
Sorafenib—Pain in extremity—Topiramate—obesity	0.000201	0.0013	CcSEcCtD
Sorafenib—Angioedema—Sibutramine—obesity	0.000199	0.00129	CcSEcCtD
Sorafenib—ABCC2—digestive system—obesity	0.000199	0.0018	CbGeAlD
Sorafenib—Angiopathy—Bupropion—obesity	0.000198	0.00128	CcSEcCtD
Sorafenib—Nausea—Cimetidine—obesity	0.000198	0.00128	CcSEcCtD
Sorafenib—Immune system disorder—Bupropion—obesity	0.000197	0.00128	CcSEcCtD
Sorafenib—KIT—liver—obesity	0.000197	0.00178	CbGeAlD
Sorafenib—Mediastinal disorder—Bupropion—obesity	0.000197	0.00128	CcSEcCtD
Sorafenib—Cough—Orlistat—obesity	0.000197	0.00127	CcSEcCtD
Sorafenib—ABCC4—adrenal gland—obesity	0.000196	0.00177	CbGeAlD
Sorafenib—Syncope—Sibutramine—obesity	0.000196	0.00127	CcSEcCtD
Sorafenib—Leukopenia—Sibutramine—obesity	0.000195	0.00126	CcSEcCtD
Sorafenib—Arrhythmia—Bupropion—obesity	0.000195	0.00126	CcSEcCtD
Sorafenib—HTR2B—adrenal gland—obesity	0.000195	0.00176	CbGeAlD
Sorafenib—Alopecia—Bupropion—obesity	0.000193	0.00125	CcSEcCtD
Sorafenib—PDGFRB—liver—obesity	0.000193	0.00174	CbGeAlD
Sorafenib—Myalgia—Orlistat—obesity	0.000192	0.00124	CcSEcCtD
Sorafenib—Loss of consciousness—Sibutramine—obesity	0.000192	0.00124	CcSEcCtD
Sorafenib—ABCG2—adrenal cortex—obesity	0.000192	0.00173	CbGeAlD
Sorafenib—Mental disorder—Bupropion—obesity	0.000192	0.00124	CcSEcCtD
Sorafenib—Mood swings—Topiramate—obesity	0.000191	0.00123	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Orlistat—obesity	0.000191	0.00123	CcSEcCtD
Sorafenib—Cough—Sibutramine—obesity	0.000191	0.00123	CcSEcCtD
Sorafenib—Malnutrition—Bupropion—obesity	0.00019	0.00123	CcSEcCtD
Sorafenib—ABCC2—adrenal gland—obesity	0.00019	0.00172	CbGeAlD
Sorafenib—Hypertension—Sibutramine—obesity	0.000188	0.00122	CcSEcCtD
Sorafenib—Dry mouth—Orlistat—obesity	0.000188	0.00122	CcSEcCtD
Sorafenib—Dehydration—Topiramate—obesity	0.000187	0.00121	CcSEcCtD
Sorafenib—Dysgeusia—Bupropion—obesity	0.000186	0.00121	CcSEcCtD
Sorafenib—Myalgia—Sibutramine—obesity	0.000186	0.0012	CcSEcCtD
Sorafenib—Arthralgia—Sibutramine—obesity	0.000186	0.0012	CcSEcCtD
Sorafenib—Anaphylactic shock—Orlistat—obesity	0.000184	0.00119	CcSEcCtD
Sorafenib—Abdominal pain upper—Topiramate—obesity	0.000184	0.00119	CcSEcCtD
Sorafenib—Hypokalaemia—Topiramate—obesity	0.000183	0.00119	CcSEcCtD
Sorafenib—Muscle spasms—Bupropion—obesity	0.000183	0.00118	CcSEcCtD
Sorafenib—Infection—Orlistat—obesity	0.000183	0.00118	CcSEcCtD
Sorafenib—Breast disorder—Topiramate—obesity	0.000182	0.00118	CcSEcCtD
Sorafenib—Dry mouth—Sibutramine—obesity	0.000182	0.00118	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Topiramate—obesity	0.000181	0.00117	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Topiramate—obesity	0.000181	0.00117	CcSEcCtD
Sorafenib—Nervous system disorder—Orlistat—obesity	0.000181	0.00117	CcSEcCtD
Sorafenib—Nasopharyngitis—Topiramate—obesity	0.00018	0.00117	CcSEcCtD
Sorafenib—Skin disorder—Orlistat—obesity	0.000179	0.00116	CcSEcCtD
Sorafenib—Gastritis—Topiramate—obesity	0.000178	0.00115	CcSEcCtD
Sorafenib—Anaphylactic shock—Sibutramine—obesity	0.000178	0.00115	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Topiramate—obesity	0.000178	0.00115	CcSEcCtD
Sorafenib—Infection—Sibutramine—obesity	0.000177	0.00115	CcSEcCtD
Sorafenib—CYP2B6—adrenal cortex—obesity	0.000177	0.0016	CbGeAlD
Sorafenib—Anaemia—Bupropion—obesity	0.000176	0.00114	CcSEcCtD
Sorafenib—Shock—Sibutramine—obesity	0.000175	0.00113	CcSEcCtD
Sorafenib—Thrombocytopenia—Sibutramine—obesity	0.000174	0.00113	CcSEcCtD
Sorafenib—Dysphagia—Topiramate—obesity	0.000174	0.00113	CcSEcCtD
Sorafenib—Angioedema—Bupropion—obesity	0.000174	0.00113	CcSEcCtD
Sorafenib—Skin disorder—Sibutramine—obesity	0.000173	0.00112	CcSEcCtD
Sorafenib—CYP2C19—digestive system—obesity	0.000171	0.00155	CbGeAlD
Sorafenib—Syncope—Bupropion—obesity	0.000171	0.0011	CcSEcCtD
Sorafenib—Pancreatitis—Topiramate—obesity	0.000171	0.0011	CcSEcCtD
Sorafenib—Leukopenia—Bupropion—obesity	0.00017	0.0011	CcSEcCtD
Sorafenib—ABCC4—endocrine gland—obesity	0.00017	0.00154	CbGeAlD
Sorafenib—Anorexia—Sibutramine—obesity	0.00017	0.0011	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Orlistat—obesity	0.000168	0.00109	CcSEcCtD
Sorafenib—Loss of consciousness—Bupropion—obesity	0.000167	0.00108	CcSEcCtD
Sorafenib—Abdominal discomfort—Topiramate—obesity	0.000167	0.00108	CcSEcCtD
Sorafenib—Cough—Bupropion—obesity	0.000166	0.00107	CcSEcCtD
Sorafenib—ABCC2—endocrine gland—obesity	0.000165	0.00149	CbGeAlD
Sorafenib—Hypertension—Bupropion—obesity	0.000164	0.00106	CcSEcCtD
Sorafenib—Neutropenia—Topiramate—obesity	0.000163	0.00105	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Sibutramine—obesity	0.000162	0.00105	CcSEcCtD
Sorafenib—Dyspepsia—Orlistat—obesity	0.000162	0.00105	CcSEcCtD
Sorafenib—Myalgia—Bupropion—obesity	0.000162	0.00105	CcSEcCtD
Sorafenib—Arthralgia—Bupropion—obesity	0.000162	0.00105	CcSEcCtD
Sorafenib—CYP2B6—cardiovascular system—obesity	0.000161	0.00146	CbGeAlD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Bupropion—obesity	0.000161	0.00104	CcSEcCtD
Sorafenib—Erectile dysfunction—Topiramate—obesity	0.00016	0.00104	CcSEcCtD
Sorafenib—Decreased appetite—Orlistat—obesity	0.00016	0.00104	CcSEcCtD
Sorafenib—CYP2C9—cardiovascular system—obesity	0.00016	0.00145	CbGeAlD
Sorafenib—CYP2C8—pituitary gland—obesity	0.000159	0.00144	CbGeAlD
Sorafenib—Gastrointestinal disorder—Orlistat—obesity	0.000159	0.00103	CcSEcCtD
Sorafenib—Dyspnoea—Sibutramine—obesity	0.000159	0.00103	CcSEcCtD
Sorafenib—Fatigue—Orlistat—obesity	0.000159	0.00103	CcSEcCtD
Sorafenib—Dry mouth—Bupropion—obesity	0.000158	0.00103	CcSEcCtD
Sorafenib—Weight decreased—Topiramate—obesity	0.000157	0.00102	CcSEcCtD
Sorafenib—Pain—Orlistat—obesity	0.000157	0.00102	CcSEcCtD
Sorafenib—Dyspepsia—Sibutramine—obesity	0.000157	0.00101	CcSEcCtD
Sorafenib—Pneumonia—Topiramate—obesity	0.000156	0.00101	CcSEcCtD
Sorafenib—Anaphylactic shock—Bupropion—obesity	0.000155	0.00101	CcSEcCtD
Sorafenib—Infestation—Topiramate—obesity	0.000155	0.001	CcSEcCtD
Sorafenib—Infestation NOS—Topiramate—obesity	0.000155	0.001	CcSEcCtD
Sorafenib—ABCG2—pituitary gland—obesity	0.000155	0.0014	CbGeAlD
Sorafenib—Decreased appetite—Sibutramine—obesity	0.000155	0.001	CcSEcCtD
Sorafenib—ABCG2—adipose tissue—obesity	0.000154	0.0014	CbGeAlD
Sorafenib—Infection—Bupropion—obesity	0.000154	0.000999	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Topiramate—obesity	0.000154	0.000995	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Sibutramine—obesity	0.000154	0.000995	CcSEcCtD
Sorafenib—ABCC4—liver—obesity	0.000153	0.00139	CbGeAlD
Sorafenib—Shock—Bupropion—obesity	0.000153	0.000989	CcSEcCtD
Sorafenib—Renal failure—Topiramate—obesity	0.000153	0.000987	CcSEcCtD
Sorafenib—Pain—Sibutramine—obesity	0.000152	0.000986	CcSEcCtD
Sorafenib—Constipation—Sibutramine—obesity	0.000152	0.000986	CcSEcCtD
Sorafenib—Nervous system disorder—Bupropion—obesity	0.000152	0.000986	CcSEcCtD
Sorafenib—Neuropathy peripheral—Topiramate—obesity	0.000152	0.000984	CcSEcCtD
Sorafenib—Thrombocytopenia—Bupropion—obesity	0.000152	0.000984	CcSEcCtD
Sorafenib—Stomatitis—Topiramate—obesity	0.000151	0.000979	CcSEcCtD
Sorafenib—Skin disorder—Bupropion—obesity	0.000151	0.000976	CcSEcCtD
Sorafenib—Gastrointestinal pain—Orlistat—obesity	0.000151	0.000974	CcSEcCtD
Sorafenib—ABCC2—liver—obesity	0.000148	0.00134	CbGeAlD
Sorafenib—Anorexia—Bupropion—obesity	0.000148	0.000958	CcSEcCtD
Sorafenib—Epistaxis—Topiramate—obesity	0.000146	0.000947	CcSEcCtD
Sorafenib—Urticaria—Orlistat—obesity	0.000146	0.000946	CcSEcCtD
Sorafenib—Gastrointestinal pain—Sibutramine—obesity	0.000146	0.000943	CcSEcCtD
Sorafenib—Abdominal pain—Orlistat—obesity	0.000146	0.000942	CcSEcCtD
Sorafenib—Body temperature increased—Orlistat—obesity	0.000146	0.000942	CcSEcCtD
Sorafenib—CYP3A5—adipose tissue—obesity	0.000143	0.0013	CbGeAlD
Sorafenib—Urticaria—Sibutramine—obesity	0.000142	0.000916	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Bupropion—obesity	0.000142	0.000916	CcSEcCtD
Sorafenib—CYP2C19—endocrine gland—obesity	0.000141	0.00128	CbGeAlD
Sorafenib—Body temperature increased—Sibutramine—obesity	0.000141	0.000911	CcSEcCtD
Sorafenib—Abdominal pain—Sibutramine—obesity	0.000141	0.000911	CcSEcCtD
Sorafenib—Haemoglobin—Topiramate—obesity	0.00014	0.000906	CcSEcCtD
Sorafenib—CYP1A2—digestive system—obesity	0.00014	0.00126	CbGeAlD
Sorafenib—Haemorrhage—Topiramate—obesity	0.000139	0.000901	CcSEcCtD
Sorafenib—Dyspnoea—Bupropion—obesity	0.000138	0.000896	CcSEcCtD
Sorafenib—ABCG2—adrenal gland—obesity	0.000138	0.00125	CbGeAlD
Sorafenib—Urinary tract disorder—Topiramate—obesity	0.000138	0.00089	CcSEcCtD
Sorafenib—Connective tissue disorder—Topiramate—obesity	0.000137	0.000886	CcSEcCtD
Sorafenib—Dyspepsia—Bupropion—obesity	0.000137	0.000885	CcSEcCtD
Sorafenib—Urethral disorder—Topiramate—obesity	0.000137	0.000884	CcSEcCtD
Sorafenib—Hypersensitivity—Orlistat—obesity	0.000136	0.000878	CcSEcCtD
Sorafenib—Decreased appetite—Bupropion—obesity	0.000135	0.000874	CcSEcCtD
Sorafenib—CYP3A5—digestive system—obesity	0.000135	0.00122	CbGeAlD
Sorafenib—Gastrointestinal disorder—Bupropion—obesity	0.000134	0.000868	CcSEcCtD
Sorafenib—CYP2B6—digestive system—obesity	0.000134	0.00121	CbGeAlD
Sorafenib—Fatigue—Bupropion—obesity	0.000134	0.000867	CcSEcCtD
Sorafenib—Constipation—Bupropion—obesity	0.000133	0.00086	CcSEcCtD
Sorafenib—Pain—Bupropion—obesity	0.000133	0.00086	CcSEcCtD
Sorafenib—CYP2C9—digestive system—obesity	0.000133	0.0012	CbGeAlD
Sorafenib—Asthenia—Orlistat—obesity	0.000132	0.000855	CcSEcCtD
Sorafenib—Erythema multiforme—Topiramate—obesity	0.000132	0.000852	CcSEcCtD
Sorafenib—Hypersensitivity—Sibutramine—obesity	0.000131	0.000849	CcSEcCtD
Sorafenib—Pruritus—Orlistat—obesity	0.00013	0.000843	CcSEcCtD
Sorafenib—Tinnitus—Topiramate—obesity	0.00013	0.00084	CcSEcCtD
Sorafenib—Flushing—Topiramate—obesity	0.000129	0.000837	CcSEcCtD
Sorafenib—Cardiac disorder—Topiramate—obesity	0.000129	0.000837	CcSEcCtD
Sorafenib—Asthenia—Sibutramine—obesity	0.000128	0.000827	CcSEcCtD
Sorafenib—CYP2B6—adrenal gland—obesity	0.000128	0.00116	CbGeAlD
Sorafenib—CYP2C19—liver—obesity	0.000128	0.00115	CbGeAlD
Sorafenib—Gastrointestinal pain—Bupropion—obesity	0.000127	0.000822	CcSEcCtD
Sorafenib—Angiopathy—Topiramate—obesity	0.000126	0.000818	CcSEcCtD
Sorafenib—Pruritus—Sibutramine—obesity	0.000126	0.000816	CcSEcCtD
Sorafenib—Diarrhoea—Orlistat—obesity	0.000126	0.000815	CcSEcCtD
Sorafenib—Immune system disorder—Topiramate—obesity	0.000126	0.000814	CcSEcCtD
Sorafenib—Mediastinal disorder—Topiramate—obesity	0.000126	0.000812	CcSEcCtD
Sorafenib—CYP2C8—endocrine gland—obesity	0.000123	0.00112	CbGeAlD
Sorafenib—Urticaria—Bupropion—obesity	0.000123	0.000799	CcSEcCtD
Sorafenib—Alopecia—Topiramate—obesity	0.000123	0.000797	CcSEcCtD
Sorafenib—Body temperature increased—Bupropion—obesity	0.000123	0.000795	CcSEcCtD
Sorafenib—Abdominal pain—Bupropion—obesity	0.000123	0.000795	CcSEcCtD
Sorafenib—Mental disorder—Topiramate—obesity	0.000122	0.00079	CcSEcCtD
Sorafenib—Diarrhoea—Sibutramine—obesity	0.000122	0.000789	CcSEcCtD
Sorafenib—Dizziness—Orlistat—obesity	0.000122	0.000788	CcSEcCtD
Sorafenib—Malnutrition—Topiramate—obesity	0.000121	0.000785	CcSEcCtD
Sorafenib—Erythema—Topiramate—obesity	0.000121	0.000785	CcSEcCtD
Sorafenib—ABCB1—islet of Langerhans—obesity	0.000119	0.00108	CbGeAlD
Sorafenib—Dysgeusia—Topiramate—obesity	0.000119	0.000768	CcSEcCtD
Sorafenib—Dizziness—Sibutramine—obesity	0.000118	0.000762	CcSEcCtD
Sorafenib—Vomiting—Orlistat—obesity	0.000117	0.000757	CcSEcCtD
Sorafenib—Muscle spasms—Topiramate—obesity	0.000117	0.000754	CcSEcCtD
Sorafenib—Rash—Orlistat—obesity	0.000116	0.000751	CcSEcCtD
Sorafenib—Dermatitis—Orlistat—obesity	0.000116	0.00075	CcSEcCtD
Sorafenib—CYP1A2—endocrine gland—obesity	0.000116	0.00105	CbGeAlD
Sorafenib—Headache—Orlistat—obesity	0.000115	0.000746	CcSEcCtD
Sorafenib—Hypersensitivity—Bupropion—obesity	0.000114	0.000741	CcSEcCtD
Sorafenib—Vomiting—Sibutramine—obesity	0.000113	0.000733	CcSEcCtD
Sorafenib—ABCB1—respiratory system—obesity	0.000113	0.00102	CbGeAlD
Sorafenib—Rash—Sibutramine—obesity	0.000112	0.000727	CcSEcCtD
Sorafenib—Dermatitis—Sibutramine—obesity	0.000112	0.000726	CcSEcCtD
Sorafenib—Anaemia—Topiramate—obesity	0.000112	0.000725	CcSEcCtD
Sorafenib—Headache—Sibutramine—obesity	0.000112	0.000722	CcSEcCtD
Sorafenib—Asthenia—Bupropion—obesity	0.000111	0.000721	CcSEcCtD
Sorafenib—CYP3A5—endocrine gland—obesity	0.000111	0.00101	CbGeAlD
Sorafenib—CYP2C8—liver—obesity	0.000111	0.00101	CbGeAlD
Sorafenib—CYP2B6—endocrine gland—obesity	0.000111	0.001	CbGeAlD
Sorafenib—Pruritus—Bupropion—obesity	0.00011	0.000711	CcSEcCtD
Sorafenib—CYP2C9—endocrine gland—obesity	0.00011	0.000992	CbGeAlD
Sorafenib—Nausea—Orlistat—obesity	0.000109	0.000708	CcSEcCtD
Sorafenib—Syncope—Topiramate—obesity	0.000109	0.000704	CcSEcCtD
Sorafenib—Leukopenia—Topiramate—obesity	0.000109	0.000702	CcSEcCtD
Sorafenib—ABCG2—liver—obesity	0.000108	0.000979	CbGeAlD
Sorafenib—Loss of consciousness—Topiramate—obesity	0.000107	0.00069	CcSEcCtD
Sorafenib—Diarrhoea—Bupropion—obesity	0.000106	0.000688	CcSEcCtD
Sorafenib—Nausea—Sibutramine—obesity	0.000106	0.000685	CcSEcCtD
Sorafenib—Cough—Topiramate—obesity	0.000106	0.000685	CcSEcCtD
Sorafenib—Hypertension—Topiramate—obesity	0.000105	0.000677	CcSEcCtD
Sorafenib—CYP1A2—liver—obesity	0.000104	0.000942	CbGeAlD
Sorafenib—Arthralgia—Topiramate—obesity	0.000103	0.000668	CcSEcCtD
Sorafenib—Myalgia—Topiramate—obesity	0.000103	0.000668	CcSEcCtD
Sorafenib—Dizziness—Bupropion—obesity	0.000103	0.000665	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Topiramate—obesity	0.000103	0.000663	CcSEcCtD
Sorafenib—CYP3A4—digestive system—obesity	0.000101	0.000915	CbGeAlD
Sorafenib—Dry mouth—Topiramate—obesity	0.000101	0.000653	CcSEcCtD
Sorafenib—CYP3A5—liver—obesity	0.0001	0.000909	CbGeAlD
Sorafenib—CYP2B6—liver—obesity	9.98e-05	0.000903	CbGeAlD
Sorafenib—CYP2D6—digestive system—obesity	9.96e-05	0.000901	CbGeAlD
Sorafenib—CYP2C9—liver—obesity	9.89e-05	0.000894	CbGeAlD
Sorafenib—Vomiting—Bupropion—obesity	9.88e-05	0.000639	CcSEcCtD
Sorafenib—Infection—Topiramate—obesity	9.83e-05	0.000636	CcSEcCtD
Sorafenib—Rash—Bupropion—obesity	9.79e-05	0.000634	CcSEcCtD
Sorafenib—Dermatitis—Bupropion—obesity	9.78e-05	0.000633	CcSEcCtD
Sorafenib—Shock—Topiramate—obesity	9.74e-05	0.00063	CcSEcCtD
Sorafenib—Headache—Bupropion—obesity	9.73e-05	0.00063	CcSEcCtD
Sorafenib—Nervous system disorder—Topiramate—obesity	9.7e-05	0.000628	CcSEcCtD
Sorafenib—Thrombocytopenia—Topiramate—obesity	9.69e-05	0.000627	CcSEcCtD
Sorafenib—Skin disorder—Topiramate—obesity	9.61e-05	0.000622	CcSEcCtD
Sorafenib—ABCB1—adrenal cortex—obesity	9.46e-05	0.000855	CbGeAlD
Sorafenib—Anorexia—Topiramate—obesity	9.43e-05	0.00061	CcSEcCtD
Sorafenib—Nausea—Bupropion—obesity	9.23e-05	0.000597	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Topiramate—obesity	9.02e-05	0.000583	CcSEcCtD
Sorafenib—Dyspnoea—Topiramate—obesity	8.82e-05	0.000571	CcSEcCtD
Sorafenib—Dyspepsia—Topiramate—obesity	8.71e-05	0.000564	CcSEcCtD
Sorafenib—ABCB1—cardiovascular system—obesity	8.63e-05	0.000781	CbGeAlD
Sorafenib—Decreased appetite—Topiramate—obesity	8.6e-05	0.000557	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Topiramate—obesity	8.54e-05	0.000553	CcSEcCtD
Sorafenib—Fatigue—Topiramate—obesity	8.53e-05	0.000552	CcSEcCtD
Sorafenib—Constipation—Topiramate—obesity	8.46e-05	0.000548	CcSEcCtD
Sorafenib—Pain—Topiramate—obesity	8.46e-05	0.000548	CcSEcCtD
Sorafenib—CYP3A4—endocrine gland—obesity	8.36e-05	0.000756	CbGeAlD
Sorafenib—CYP2D6—endocrine gland—obesity	8.23e-05	0.000744	CbGeAlD
Sorafenib—Gastrointestinal pain—Topiramate—obesity	8.09e-05	0.000524	CcSEcCtD
Sorafenib—Urticaria—Topiramate—obesity	7.86e-05	0.000509	CcSEcCtD
Sorafenib—Body temperature increased—Topiramate—obesity	7.82e-05	0.000506	CcSEcCtD
Sorafenib—Abdominal pain—Topiramate—obesity	7.82e-05	0.000506	CcSEcCtD
Sorafenib—ABCB1—pituitary gland—obesity	7.64e-05	0.000691	CbGeAlD
Sorafenib—ABCB1—adipose tissue—obesity	7.61e-05	0.000688	CbGeAlD
Sorafenib—CYP3A4—liver—obesity	7.54e-05	0.000682	CbGeAlD
Sorafenib—CYP2D6—liver—obesity	7.42e-05	0.000671	CbGeAlD
Sorafenib—Hypersensitivity—Topiramate—obesity	7.29e-05	0.000472	CcSEcCtD
Sorafenib—ABCB1—digestive system—obesity	7.16e-05	0.000648	CbGeAlD
Sorafenib—Asthenia—Topiramate—obesity	7.1e-05	0.000459	CcSEcCtD
Sorafenib—Pruritus—Topiramate—obesity	7e-05	0.000453	CcSEcCtD
Sorafenib—ABCB1—adrenal gland—obesity	6.83e-05	0.000617	CbGeAlD
Sorafenib—Diarrhoea—Topiramate—obesity	6.77e-05	0.000438	CcSEcCtD
Sorafenib—Dizziness—Topiramate—obesity	6.54e-05	0.000423	CcSEcCtD
Sorafenib—Vomiting—Topiramate—obesity	6.29e-05	0.000407	CcSEcCtD
Sorafenib—Rash—Topiramate—obesity	6.24e-05	0.000404	CcSEcCtD
Sorafenib—Dermatitis—Topiramate—obesity	6.23e-05	0.000403	CcSEcCtD
Sorafenib—Headache—Topiramate—obesity	6.2e-05	0.000401	CcSEcCtD
Sorafenib—ABCB1—endocrine gland—obesity	5.92e-05	0.000535	CbGeAlD
Sorafenib—Nausea—Topiramate—obesity	5.88e-05	0.00038	CcSEcCtD
Sorafenib—ABCB1—liver—obesity	5.34e-05	0.000483	CbGeAlD
Sorafenib—FGFR1—Signaling Pathways—TGFB1—obesity	9.58e-07	5.09e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MYC—obesity	9.57e-07	5.09e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TGFB1—obesity	9.55e-07	5.08e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—PIK3CA—obesity	9.54e-07	5.07e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—PIK3CA—obesity	9.52e-07	5.06e-06	CbGpPWpGaD
Sorafenib—FGFR1—Disease—AKT1—obesity	9.51e-07	5.05e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GPX1—obesity	9.49e-07	5.05e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—obesity	9.49e-07	5.04e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—AKT1—obesity	9.48e-07	5.04e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—PIK3CA—obesity	9.43e-07	5.02e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SREBF1—obesity	9.43e-07	5.01e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARA—obesity	9.43e-07	5.01e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CD—obesity	9.39e-07	4.99e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—MTHFR—obesity	9.38e-07	4.99e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CD36—obesity	9.33e-07	4.96e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—PIK3CA—obesity	9.32e-07	4.95e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—obesity	9.31e-07	4.95e-06	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—AKT1—obesity	9.28e-07	4.94e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—STAT3—obesity	9.28e-07	4.94e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ALB—obesity	9.27e-07	4.93e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—COMT—obesity	9.26e-07	4.92e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—obesity	9.26e-07	4.92e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—AKT1—obesity	9.25e-07	4.92e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CD36—obesity	9.25e-07	4.92e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PIK3CB—obesity	9.24e-07	4.91e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MTOR—obesity	9.24e-07	4.91e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARA—obesity	9.2e-07	4.89e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CD—obesity	9.18e-07	4.88e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GOT2—obesity	9.18e-07	4.88e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GNB3—obesity	9.13e-07	4.86e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARGC1A—obesity	9.13e-07	4.86e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AGT—obesity	9.13e-07	4.85e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—HMOX1—obesity	9.09e-07	4.83e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ALB—obesity	9.06e-07	4.82e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MAPK8—obesity	9.05e-07	4.81e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—AKT1—obesity	9.05e-07	4.81e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CG—obesity	9.05e-07	4.81e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—AKT1—obesity	9.03e-07	4.8e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—FASN—obesity	8.98e-07	4.77e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—APOE—obesity	8.95e-07	4.76e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—BCHE—obesity	8.94e-07	4.75e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—obesity	8.94e-07	4.75e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AGT—obesity	8.91e-07	4.74e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GNAS—obesity	8.89e-07	4.73e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—NOS3—obesity	8.87e-07	4.71e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3R1—obesity	8.87e-07	4.71e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CAV1—obesity	8.86e-07	4.71e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—STAT3—obesity	8.85e-07	4.71e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—APOA1—obesity	8.84e-07	4.7e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—MTHFR—obesity	8.84e-07	4.7e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—MTHFR—obesity	8.76e-07	4.66e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—APOE—obesity	8.73e-07	4.64e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PPARG—obesity	8.73e-07	4.64e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APOB—obesity	8.71e-07	4.63e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARA—obesity	8.67e-07	4.61e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—NOS3—obesity	8.67e-07	4.61e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3R1—obesity	8.67e-07	4.61e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CAV1—obesity	8.65e-07	4.6e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—APOA1—obesity	8.63e-07	4.59e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP2E1—obesity	8.63e-07	4.59e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MYC—obesity	8.63e-07	4.59e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—POMC—obesity	8.61e-07	4.58e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TGFB1—obesity	8.6e-07	4.57e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARA—obesity	8.6e-07	4.57e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PIK3CA—obesity	8.59e-07	4.56e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PIK3CA—obesity	8.59e-07	4.56e-06	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—AKT1—obesity	8.58e-07	4.56e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—INS—obesity	8.56e-07	4.55e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—AKT1—obesity	8.54e-07	4.54e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NQO1—obesity	8.53e-07	4.54e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—obesity	8.47e-07	4.5e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—obesity	8.45e-07	4.49e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—obesity	8.43e-07	4.48e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AGT—obesity	8.4e-07	4.46e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—obesity	8.35e-07	4.44e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AGT—obesity	8.32e-07	4.43e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—LPL—obesity	8.32e-07	4.42e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—STAT3—obesity	8.27e-07	4.4e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—obesity	8.25e-07	4.39e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—AKT1—obesity	8.25e-07	4.38e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—APOE—obesity	8.23e-07	4.37e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MYC—obesity	8.23e-07	4.37e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TGFB1—obesity	8.21e-07	4.36e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CB—obesity	8.19e-07	4.35e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GCG—obesity	8.18e-07	4.35e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SLC2A4—obesity	8.18e-07	4.35e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—APOE—obesity	8.16e-07	4.34e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CAV1—obesity	8.15e-07	4.33e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PIK3CA—obesity	8.15e-07	4.33e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—APOA1—obesity	8.13e-07	4.32e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PIK3CA—obesity	8.13e-07	4.32e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GPX1—obesity	8.11e-07	4.31e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—obesity	8.11e-07	4.31e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CAV1—obesity	8.08e-07	4.3e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CG—obesity	8.07e-07	4.29e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYCS—obesity	8.07e-07	4.29e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—APOA1—obesity	8.06e-07	4.29e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—obesity	8.03e-07	4.27e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PIK3CA—obesity	8.02e-07	4.27e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PIK3CA—obesity	8.02e-07	4.27e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CB—obesity	8e-07	4.25e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CD—obesity	7.95e-07	4.23e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—obesity	7.93e-07	4.22e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GOT1—obesity	7.92e-07	4.21e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GGT1—obesity	7.92e-07	4.21e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CD36—obesity	7.9e-07	4.2e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CG—obesity	7.88e-07	4.19e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ALB—obesity	7.85e-07	4.17e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MAPK8—obesity	7.81e-07	4.15e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NCOA1—obesity	7.8e-07	4.15e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARG—obesity	7.79e-07	4.14e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AKT1—obesity	7.79e-07	4.14e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AKT1—obesity	7.78e-07	4.14e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—obesity	7.72e-07	4.1e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AKT1—obesity	7.71e-07	4.1e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP19A1—obesity	7.69e-07	4.09e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—STK11—obesity	7.69e-07	4.09e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MYC—obesity	7.69e-07	4.09e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—POMC—obesity	7.68e-07	4.09e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TGFB1—obesity	7.67e-07	4.08e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—INS—obesity	7.64e-07	4.06e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—AKT1—obesity	7.61e-07	4.05e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARG—obesity	7.61e-07	4.04e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—obesity	7.6e-07	4.04e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—obesity	7.6e-07	4.04e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—NOS3—obesity	7.51e-07	3.99e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3R1—obesity	7.51e-07	3.99e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—POMC—obesity	7.5e-07	3.99e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—MTHFR—obesity	7.49e-07	3.98e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—INS—obesity	7.46e-07	3.97e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CG—obesity	7.43e-07	3.95e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CG—obesity	7.36e-07	3.91e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARA—obesity	7.35e-07	3.91e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PIK3CA—obesity	7.32e-07	3.89e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—obesity	7.22e-07	3.84e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—obesity	7.2e-07	3.83e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARG—obesity	7.17e-07	3.81e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—COMT—obesity	7.15e-07	3.8e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—STAT3—obesity	7.14e-07	3.8e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AGT—obesity	7.11e-07	3.78e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARG—obesity	7.1e-07	3.78e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CD—obesity	7.1e-07	3.77e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—POMC—obesity	7.07e-07	3.76e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARGC1A—obesity	7.05e-07	3.75e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GNB3—obesity	7.05e-07	3.75e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—INS—obesity	7.03e-07	3.74e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—HMOX1—obesity	7.02e-07	3.73e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AKT1—obesity	7.01e-07	3.73e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AKT1—obesity	7.01e-07	3.73e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—POMC—obesity	7.01e-07	3.73e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ALB—obesity	7.01e-07	3.72e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PIK3CA—obesity	6.98e-07	3.71e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APOE—obesity	6.97e-07	3.71e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—INS—obesity	6.97e-07	3.7e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CB—obesity	6.93e-07	3.68e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CD—obesity	6.93e-07	3.68e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CAV1—obesity	6.91e-07	3.67e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APOA1—obesity	6.89e-07	3.66e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—obesity	6.87e-07	3.65e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GNAS—obesity	6.86e-07	3.65e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ALB—obesity	6.84e-07	3.64e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PIK3CA—obesity	6.81e-07	3.62e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PIK3CA—obesity	6.75e-07	3.59e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOB—obesity	6.72e-07	3.57e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3R1—obesity	6.7e-07	3.56e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—NOS3—obesity	6.7e-07	3.56e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AKT1—obesity	6.66e-07	3.54e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AKT1—obesity	6.64e-07	3.53e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MYC—obesity	6.64e-07	3.53e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TGFB1—obesity	6.62e-07	3.52e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—obesity	6.6e-07	3.51e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—AKT1—obesity	6.55e-07	3.48e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—AKT1—obesity	6.55e-07	3.48e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—NOS3—obesity	6.54e-07	3.48e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3R1—obesity	6.54e-07	3.48e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CD—obesity	6.53e-07	3.47e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PIK3CA—obesity	6.53e-07	3.47e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—obesity	6.48e-07	3.45e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CD—obesity	6.47e-07	3.44e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ALB—obesity	6.44e-07	3.43e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—LPL—obesity	6.42e-07	3.41e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ALB—obesity	6.39e-07	3.4e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CG—obesity	6.29e-07	3.34e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GPX1—obesity	6.26e-07	3.33e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CB—obesity	6.19e-07	3.29e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—obesity	6.18e-07	3.29e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3R1—obesity	6.16e-07	3.28e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—NOS3—obesity	6.16e-07	3.28e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—obesity	6.13e-07	3.26e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—NOS3—obesity	6.11e-07	3.25e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3R1—obesity	6.11e-07	3.25e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CD36—obesity	6.1e-07	3.24e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARG—obesity	6.07e-07	3.23e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CB—obesity	6.04e-07	3.21e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—POMC—obesity	5.99e-07	3.18e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—obesity	5.98e-07	3.18e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AKT1—obesity	5.98e-07	3.18e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—INS—obesity	5.95e-07	3.17e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—obesity	5.78e-07	3.07e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MTHFR—obesity	5.78e-07	3.07e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AKT1—obesity	5.7e-07	3.03e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CB—obesity	5.69e-07	3.02e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARA—obesity	5.67e-07	3.01e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CB—obesity	5.64e-07	3e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—obesity	5.64e-07	3e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PIK3CA—obesity	5.63e-07	3e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—obesity	5.59e-07	2.97e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—AKT1—obesity	5.56e-07	2.96e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CD—obesity	5.53e-07	2.94e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—AKT1—obesity	5.51e-07	2.93e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AGT—obesity	5.49e-07	2.92e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ALB—obesity	5.46e-07	2.9e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOE—obesity	5.38e-07	2.86e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AKT1—obesity	5.33e-07	2.83e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CAV1—obesity	5.33e-07	2.83e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOA1—obesity	5.32e-07	2.83e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—NOS3—obesity	5.22e-07	2.78e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3R1—obesity	5.22e-07	2.78e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CA—obesity	4.99e-07	2.65e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—obesity	4.99e-07	2.65e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CA—obesity	4.88e-07	2.59e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CG—obesity	4.85e-07	2.58e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CB—obesity	4.82e-07	2.56e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—obesity	4.78e-07	2.54e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARG—obesity	4.69e-07	2.49e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—POMC—obesity	4.62e-07	2.46e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AKT1—obesity	4.6e-07	2.45e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—INS—obesity	4.6e-07	2.44e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CD—obesity	4.27e-07	2.27e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CA—obesity	4.23e-07	2.25e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALB—obesity	4.21e-07	2.24e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AKT1—obesity	4.08e-07	2.17e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3R1—obesity	4.03e-07	2.14e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NOS3—obesity	4.03e-07	2.14e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AKT1—obesity	3.98e-07	2.12e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CA—obesity	3.77e-07	2e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CB—obesity	3.72e-07	1.98e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—obesity	3.69e-07	1.96e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CA—obesity	3.68e-07	1.96e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CA—obesity	3.47e-07	1.84e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AKT1—obesity	3.45e-07	1.83e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CA—obesity	3.44e-07	1.83e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AKT1—obesity	3.08e-07	1.64e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AKT1—obesity	3.01e-07	1.6e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CA—obesity	2.94e-07	1.56e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AKT1—obesity	2.83e-07	1.51e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AKT1—obesity	2.81e-07	1.49e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AKT1—obesity	2.4e-07	1.28e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CA—obesity	2.27e-07	1.21e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKT1—obesity	1.85e-07	9.85e-07	CbGpPWpGaD
